Bio-Thera Solutions,Ltd. (688177.SH) announced that the company has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for its investigational drug, recombinant humanized anti-VEGF monoclonal antibody injection (BAT5906), for additional indications including macular edema caused by central retinal vein occlusion (CRVO-ME) and choroidal neovascularization in pathological myopia (pmCNV).
According to the announcement, BAT5906 is an innovative recombinant humanized monoclonal antibody drug independently developed and produced by Bio-Thera Solutions,Ltd. It is a full-length IgG1 antibody with a molecular weight of 149KDa, capable of specifically binding to human VEGF-A165 and inhibiting angiogenesis. In in vitro angiogenesis models, BAT5906 can block the binding of VEGF to its corresponding receptors, inhibiting endothelial cell proliferation and neovascularization.
In animal studies, BAT5906 demonstrated a longer serum half-life compared to ranibizumab, which has a Fab fragment structure, potentially supporting longer injection intervals in clinical applications. Regarding drug safety, BAT5906 does not trigger antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in minimal systemic adverse reactions and potentially safer clinical applications.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。